Alpha-lipoic acid (ALA) has long been considered a potential treatment option for diabetic polyneuropathy (DPN). However, a recent Cochrane review has raised significant doubts about its effectiveness. The analysis revealed no notable advantages of ALA over placebo in alleviating symptoms or neurological impairments. Furthermore, the safety profile between the two groups was largely comparable.
This review draws upon three randomized, placebo-controlled studies that collectively evaluated 816 adults suffering from symptomatic diabetic polyneuropathy for a minimum of six months.
A Common Complication of Diabetes
Diabetic polyneuropathy is among the most prevalent complications associated with diabetes mellitus. It’s estimated that approximately one-third of individuals with diabetes will develop some form of nerve damage over the course of the disease. Typical manifestations include pain, tingling, burning sensations, or numbness, especially in the feet. The condition significantly raises the risk of diabetic foot ulcers and non-traumatic amputations.
The exact mechanisms leading to diabetic polyneuropathy are still not completely understood. Besides chronic hyperglycemia, inflammation and oxidative stress are also discussed as possible contributing factors.
Alpha-Lipoic Acid: The Hopeful Candidate
Alpha-lipoic acid, sometimes referred to as thioctic acid, is a naturally occurring sulfur compound with antioxidant properties. It is believed to help regenerate endogenous antioxidants, reduce inflammation, and enhance glucose uptake into cells. These mechanisms have prompted its long-standing use as a treatment for diabetic polyneuropathy. The authors of the Cochrane review aimed to assess whether this theoretical benefit translates into significant clinical improvements for patients.
No Significant Impact on Symptoms
As a primary endpoint, researchers monitored changes in neuropathic symptoms at six months post-treatment initiation. Additionally, symptoms were evaluated at the 24-month mark, alongside neurological impairments at both time points.
The findings indicated that ALA did not significantly improve patient symptoms when compared to placebo, neither at six months nor at 24 months. No clinically meaningful differences were observed concerning neurological impairments between the treatment groups.
No Difference in Side Effects
The study also examined the safety of ALA treatment. Remarkably, there was no significant difference in adverse effects that led to therapy withdrawal. This suggests that while ALA poses no additional risks, it also does not confer any demonstrable clinical benefit compared to a placebo.
Limited Validity of the Data
The authors highlighted several limitations in the analysis. Only three studies were available for review, with relatively small participant numbers and varying dosages. Depending on the study, daily doses of ALA ranged from 600 mg to 1800 mg, administered both orally and intravenously.
Moreover, methodological uncertainties and wide confidence intervals further compromised the interpretability of the results. Consequently, the evidence was rated as moderate to low based on the endpoints examined.
Despite these limitations, the current data do not suggest that ALA meaningfully improves the symptoms or neurological impairments of diabetic polyneuropathy compared to placebo. This analysis, titled “Alpha-lipoic acid for diabetic peripheral neuropathy,” was published in the American Family Physician and is rooted in the Cochrane review.
